← Back to Search

LivaNova Inspire for Thrombocytopenia

N/A
Recruiting
Led By Braden Dulong, MD
Research Sponsored by BRADEN DULONG
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 hours from start of surgery (measured at the end of cardiopulmonary bypass)
Awards & highlights

Study Summary

This trial will study the effects of a heart-lung machine on platelet function to determine if they increase the risk of patients bleeding during/after open-heart surgery.

Who is the study for?
Adults scheduled for non-emergency heart surgery with expected long cardiopulmonary bypass times can join. Excluded are those under 18, with bleeding disorders, recent clots or strokes, severe kidney/liver disease, anemia, on certain blood thinners recently (except ASA), pregnant women, and anyone unable to consent.Check my eligibility
What is being tested?
The trial is testing if different oxygenators used in heart-lung machines during open-heart surgery affect platelet function and clotting. It compares Terumo and LivaNova oxygenators using Plateletworks tests and rotational thromboelastometry to assess patient bleeding risks.See study design
What are the potential side effects?
There may not be direct side effects from the interventions as this study focuses on equipment used during surgery rather than medications. However, there's a potential risk of increased bleeding due to altered platelet function.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 hours from start of surgery (measured at the end of cardiopulmonary bypass)
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 hours from start of surgery (measured at the end of cardiopulmonary bypass) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Blood Platelets
Blood Platelets
Platelet Count measurement
Secondary outcome measures
ROTEM change in functional platelets
Other outcome measures
Cardiopulmonary Bypass

Trial Design

2Treatment groups
Active Control
Group I: LivaNova InspireActive Control1 Intervention
A high pressure oxygenator (LivaNova) will be used during cardiopulmonary bypass.
Group II: TerumoActive Control1 Intervention
A low pressure oxygenator (Terumo) will be used during cardiopulmonary bypass.

Find a Location

Who is running the clinical trial?

BRADEN DULONGLead Sponsor
Braden DulongLead Sponsor
Braden Dulong, MDPrincipal InvestigatorNova Scotia Health

Media Library

Cardiopulmonary Bypass Clinical Trial Eligibility Overview. Trial Name: NCT05588011 — N/A
Thrombocytopenia Research Study Groups: LivaNova Inspire, Terumo
Thrombocytopenia Clinical Trial 2023: Cardiopulmonary Bypass Highlights & Side Effects. Trial Name: NCT05588011 — N/A
Cardiopulmonary Bypass 2023 Treatment Timeline for Medical Study. Trial Name: NCT05588011 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many patients are taking part in this experiment at most?

"Yes, the most recent information available on clinicaltrials.gov suggests that this trial is still looking for patients to enroll. The study was first posted on October 7th of this year, and was last updated on the 17th. They are hoping to find 70 people total from a single location."

Answered by AI

Can people with the condition still sign up for the trial?

"The study is still recruiting patients, with the latest edit to the posting on clinicaltrials.gov being on 10/17/2022."

Answered by AI
~20 spots leftby Dec 2024